Filtered By:
Source: Cancer Research
Cancer: Epithelial Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 126 results found since Jan 2013.
Abstract P6-11-10: Preclinical efficacy of the novel PIM2 kinase inhibitor, JP11646 in triple negative breast cancer models
Conclusions: PIM2 upregulation in TNBC cell line resulted in more aggressive phenotype. JP11646, through novel mechanism of action resulting in degradation of PIM2, showed robust activity in TNBC cell lines both in vitro and in vivo. Further correlative studies in tumors harvested from in vivo experiments are ongoing. These results encourage further exploration of use of JP11646 as a targeted agent in treatment of TNBC.Citation Format: Mehta R, Kothai Guruswamy Sangameswaran D, Bezbatchenko K, Moore J, Gil M, Khoury T, Baldino C, Caserta J, Fetterly, Jr. G, Lee K, Adjei A, Opyrchal M. Preclinical efficacy of the novel PIM2...
Source: Cancer Research - February 28, 2017 Category: Cancer & Oncology Authors: R Mehta, D Kothai Guruswamy Sangameswaran, K Bezbatchenko, J Moore, M Gil, T Khoury, C Baldino, J Caserta, G Fetterly, Jr., K Lee, A Adjei, M Opyrchal Tags: Poster Session Abstracts Source Type: research
Abstract P3-13-28: Lipofilling of the axilla to reduce secondary lymphedema after axillary lymph node dissection
Conclusions: PIM2 upregulation in TNBC cell line resulted in more aggressive phenotype. JP11646, through novel mechanism of action resulting in degradation of PIM2, showed robust activity in TNBC cell lines both in vitro and in vivo. Further correlative studies in tumors harvested from in vivo experiments are ongoing. These results encourage further exploration of use of JP11646 as a targeted agent in treatment of TNBC.Citation Format: Vandermeeren L, Belgrado J-P, Vankerckhove S, Valsamis J-B, Feipel V, Rooze M, Moraine J-J, Hertens D, Carly B, Liebens F. Lipofilling of the axilla to reduce secondary lymphedema after axil...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: L Vandermeeren, J-P Belgrado, S Vankerckhove, J-B Valsamis, V Feipel, M Rooze, J-J Moraine, D Hertens, B Carly, F Liebens Tags: Poster Session Abstracts Source Type: research
Abstract P4-06-06: Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation
Conclusion: Taken together, silencing of ZBTB2 sensitize cancer cells to cisplatin through regulation of EMT markers and stem-like cell properties in TNBC. These findings suggest a novel molecular pathway targeting ZBTB2/stat3/NFkB signaling to combat drug resistance in metastatic TNBC.Citation Format: Giacchetti S, Li XM, Ozturk N, Cuvier C, Machowiak J, Arrondeau J, Chang-Marchand Y, Espié M, Okyar A, Lévi F. Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation [abstract]. In: Proceedings of the Th...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: S Giacchetti, XM Li, N Ozturk, C Cuvier, J Machowiak, J Arrondeau, Y Chang–Marchand, M Espie, A Okyar, F Levi Tags: Poster Session Abstracts Source Type: research
Abstract B05: The RNA-binding protein HuR enhances exosome secretion in colorectal cancer
Enhanced secretion of exosomes by cancer cells is recognized as a means of transferring oncogenic information within the tumor microenvironment. Through their ability to carry specific RNA and protein cargo, tumor-derived exosomes are now being recognized for their ability to impact the tumor microenvironment and as promising cancer biomarkers. However, our knowledge of the cellular factors that promote increased exosome production from tumor cells and how they impact the loading of specific tumor-promoting RNA cargo is limited. Our prior work has established that colorectal cancer (CRC) cells and tumors overexpress the ke...
Source: Cancer Research - January 30, 2017 Category: Cancer & Oncology Authors: Ranjan Preet, Wei-Ting Hung, Shufei Zhuang, Lane K. Christenson, Dan A. Dixon Tags: Screening and Early Detection Source Type: research
Abstract B45: Silencing ss3 integrin by targeted ECO/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer
Metastatic breast cancer is the second leading cause of cancer-related deaths among women. Triple-negative breast cancer (TNBC) is a highly aggressive subcategory of breast cancer and currently lacks well-defined molecular targets for effective targeted therapies. Disease relapse, metastasis, and drug resistance render standard chemotherapy ineffective in the treatment of TNBC. Because previous studies coupled β3 integrin (ITGB3) to epithelial-mesenchymal transition (EMT) and metastasis, we exploited β3 integrin as a therapeutic target to treat TNBC by delivering β3 integrin siRNA via lipid ECO-based nanoparticles (ECO/...
Source: Cancer Research - January 15, 2017 Category: Cancer & Oncology Authors: Jenny G. Parvani, Maneesh D. Gujrati, Margaret A. Mack, William P. Schiemann, Zheng-Rong Lu Tags: Drug Delivery and Nanomedicine Source Type: research
Abstract A30: Characterizing the non-linear dependency of the CDK5-Rb axis in non-small cell lung cancer
In spite of recent therapeutics advances and early detection, lung cancer is still the leading cause of cancer-associated deaths worldwide. The five-year survival rates for its two major subtypes, small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are estimated to be 6% and 18%, respectively. This high mortality is due to its aggressive nature even when detected at an early stage. Besides its aggressive nature and tendency for early metastasis, another feature of lung cancer is the inactivation of the retinoblastoma protein (Rb) that is observed in both lung cancer subtypes. NSCLC exhibits Rb inactivation...
Source: Cancer Research - January 15, 2017 Category: Cancer & Oncology Authors: Jaileene Perez-Morales, Mauricio Cabrera-Rios, Jonathan Gonzalez-Flores, Pedro Santiago-Cardona Tags: Systems Biology Source Type: research
Abstract A67: TFF (Trefoil Factor Family) is a novel tumor suppressor and can be the therapeutic target for pancreatic cancer
Conclusion: TFF1 and TFF2 act as tumor suppressor in pancreatic carcinogenesis in a different manner, and they can be a novel therapeutic target for PDAC.Citation Format: Junpei Yamaguchi, Yukihiro Yokoyama, Toshio Kokuryo, Masato Nagino.{Authors}. TFF (Trefoil Factor Family) is a novel tumor suppressor and can be the therapeutic target for pancreatic cancer. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2016 May 12-15; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(24 Suppl):Abstract nr A67.
Source: Cancer Research - December 13, 2016 Category: Cancer & Oncology Authors: Junpei Yamaguchi, Yukihiro Yokoyama, Toshio Kokuryo, Masato Nagino Tags: Early Detection Source Type: research
Abstract C05: Pulmonary laminin 332 in tumor cell migration and breast cancer survival
Metastasis to the lung often leads to the demise of the patient, thus a greater understanding of the process might lead to strategies for better cancer control. Tumor cell metastatic ability is determined by both intrinsic properties of tumor cells and contributions from the microenvironment. The goal of this study was to determine the role of the extracellular matrix protein laminin 332 (LN332) in breast cancer progression. Because tumor cell motility is a requirement for metastasis, we hypothesize that lung tissue harbors substances that induce tumor cell migration. In order to better characterize the interaction of brea...
Source: Cancer Research - July 27, 2016 Category: Cancer & Oncology Authors: Carpenter, P. M., Sivadas, P., Ziogas, A., Anton-Culver, H. Tags: Tumor Microenvironment and Metastasis Source Type: research
Abstract B22: Loss of LncRNA XIST induces Epithelial to Mesenchymal Transition in Breast Cancer
Brain is one of the major sites of metastasis of breast cancer, and approximately 20% of patients with aggressive breast cancer eventually develop the metastatic disease in the brain. Long non-coding RNAs (lncRNA) have recently drawn much attention due to their wide functional variations and potential roles in tumor progression. By performing lncRNA array analysis comparing non-metastatic primary tumors with brain metastatic tumors from breast cancer patients, we identified that lncRNA XIST expression was significantly down-regulated in brain metastatic tumors. The result of Taqman PCR validated the results in tumor sample...
Source: Cancer Research - May 25, 2016 Category: Cancer & Oncology Authors: Liu, Y., Xing, F., Wu, K., Sharma, S., Watabe, K. Tags: Genetics and Evolution of Metastatic Tumors Source Type: research
Abstract B36: Rab25 aggravates cancer cell invasion through Snail expression
Conclusion: Our results show for the first time that Snail mediates Rab25-induced cancer cell EMT and invasiveness through a beta1 integrin /Akt/GSK-3beta signaling cascade, providing novel biomarkers, and potential therapeutic targets for deadly cancers.Citation Format: Bo Young Jeong, Kyung Hwa Cho, Seung Hwa Kim, Yu Na Kim, Chang Gyo Park, Hoi Young Lee. Rab25 aggravates cancer cell invasion through Snail expression. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr B36.
Source: Cancer Research - May 25, 2016 Category: Cancer & Oncology Authors: Jeong, B. Y., Cho, K. H., Kim, S. H., Kim, Y. N., Park, C. G., Lee, H. Y. Tags: Metastatic Cell Plasticity Source Type: research
Abstract P5-03-13: The anticancer effects of Supinoxin(R) (RX-5902) in triple-negative breast cancer MDA-MB-231 through phosphorylated p68 on Tyr593
In this study, we sought to determine whether phosphorylated p68 on Tyr593 plays a key role in RX-5902's ability to inhibit cancer cell growth by knocking down p68. p68-siRNA efficiently down-regulated the expression of phosphorylated p68 on Tyr593 as well as p68 in the triple-negative (TN) breast cancer cell line, MDA-MB-231. Exposure of p68-siRNA-transfected cells to the IC50 concentration of RX-5902 protected MDA-MB-231 cells from the cytotoxic effects of RX-5902, indicating the phosphorylated p68 on Tyr593 is a key molecule for RX-5902 cytotoxic effects. We also examined the tumor growth inhibition (TGI) of RX-5902 in ...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Kim, D., Yang, M., Lee, Y., Remenyi, J., Fuller-Pace, F. Tags: Poster Session Abstracts Source Type: research
Abstract P1-05-04: A novel mechanism of epithelial-mesenchymal transition in breast cancer metastasis: Involvement of prostanoid receptor
Conclusion: Our results showed that EP2 promoted EMT and breast cancer metastasis through the downregulation of SLC19A3 expression. Taken together, targeting EP2/SLC19A3 signaling pathway maybe a potential treatment for metastasis and adjuvant chemotherapy to reduce the metastatic risk.Citation Format: Kwong A, Siu MT, Cheuk I, Ho JC, Chen J, Shin VY. A novel mechanism of epithelial-mesenchymal transition in breast cancer metastasis: Involvement of prostanoid receptor. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AA...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Kwong, A., Siu, M., Cheuk, I., Ho, J., Chen, J., Shin, V. Tags: Poster Session Abstracts Source Type: research
Abstract P1-05-06: Essential role of notch-4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer
In conclusion, inhibition of Notch signaling may have efficacy in the treatment of breast cancer metastasis.Citation Format: Bui QT, Kang KW. Essential role of notch-4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-05-06.
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Bui, Q., Kang, K. Tags: Poster Session Abstracts Source Type: research
Abstract A1-05: Elucidation of epigenetic driver genes in clear cell renal cell carcinoma using a newly developed assay, AcceSssIble
Conclusions: Our study revealed a vast number of chromatin accessibility and accompanying gene expression changes that occur in gene promoters in the development of ccRCC, both dependent and independent of DNA methylation changes. Each individual tumor has a unique profile of epigenetic alterations. Moreover, almost none of the genes that were found to undergo epigenetic and resulting gene expression changes overlap with TCGA's findings of commonly mutated genes in ccRCC. Overall, these studies represent novel approaches that can help identify new therapeutic target genes and treatment strategies for ccRCC, including perso...
Source: Cancer Research - November 15, 2015 Category: Cancer & Oncology Authors: Becket, E. C., Duymich, C., Chang, Y.-W., Pandiyan, K., Nichols, P., Jones, P., Gill, I., Liang, G. Tags: Cancer Genomics and Epigenomics Source Type: research
Abstract 12: Bclxl is a key regulator of mitochondria-induced apoptosis in ovarian cancer stem cells
Conclusion:Ovarian cancer stem cells have a unique mitochondrial phenotype and Bclxl is a key regulator of its stability and may play a role in resistance to chemotherapy-induced apoptosis. Targeting Bclxl may be an approach to complement current standard of care in ovarian cancer. The demonstration that apoptosis can be fully induced with minimal loss of Bclxl suggests an acceptable therapeutic window for Bclxl inhibitors.Citation Format: Ayesha B. Alvero, Mary Pitruzello, Michele Montagna, Eydis Lima, Gil Mor. Bclxl is a key regulator of mitochondria-induced apoptosis in ovarian cancer stem cells. [abstract]. In: Proceed...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Alvero, A. B., Pitruzello, M., Montagna, M., Lima, E., Mor, G. Tags: Molecular and Cellular Biology Source Type: research
